德国首个肿瘤PET/CT注册研究:基于实践证据的临床获益
该前瞻性注册研究在德国单中心纳入4,504例患者共5,939次PET/CT检查,可评估3,724例患者共4,754次扫描,评估PET/CT对22种肿瘤类型临床管理的影响。PET/CT使37.1%的临床管理发生改变(95% CI 35.7-38.5),最常见(30.6%)为从计划非治疗策略转为积极治疗;额外影像需求从PET/CT前的66.1%降至后的6.1%,72.7%的计划侵入性检查得以避免。
要点
- PET/CT使37.1%的临床管理发生改变(95% CI 35.7-38.5),最常见为从非治疗转为积极治疗(30.6%)。
- 额外影像需求从PET/CT前的66.1%降至后的6.1%,72.7%的计划侵入性检查得以避免。
- 21.7%的病例治疗目标改变,从根治性转为姑息性治疗的方向约为反向的两倍。
核心结论
- 这一大型前瞻性注册研究数据证实,医生常基于PET/CT改变既定管理,表现为启动治疗并减少额外影像和侵入性检查,且适用于多种肿瘤类型和适应证。
研究设计与样本
- 前瞻性患者队列注册研究,2013年4月至2016年8月在德国单大学中心纳入有临床指征的PET/CT患者。
- 注册研究共入组4,504例患者共5,939次PET/CT检查,最终可评估数据来自3,724例患者共4,754次扫描。
- 通过问卷收集申请医师在PET/CT前后对患者管理意图的数据,覆盖22种肿瘤类型及不同适应证(诊断、分期、疑似复发)和管理类别。
主要发现
- 最常见的PET/CT适应证为肿瘤分期(59.7%);黑色素瘤、肺癌、淋巴瘤、神经内分泌肿瘤和前列腺癌合计占70%的病例。
- 总体上PET/CT导致37.1%的临床管理改变(95% CI 35.7-38.5),最常见(30.6%)为从PET/CT前的计划非治疗策略转为PET/CT后的积极治疗。
- 管理改变频率范围从头颈癌的28.3%至黑色素瘤的46.0%。
- PET/CT对减少额外影像需求的影响最大,额外影像需求从PET/CT前的66.1%降至PET/CT后的6.1%。
- 72.7%的PET/CT前计划的侵入性检查得以避免;21.7%的病例PET/CT后治疗目标改变,从根治性转为姑息性治疗的方向约为反向的两倍。
临床怎么用
- 研究结果为与公共健康保险就PET/CT覆盖范围进行咨询提供依据。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate the impact of PET/CT on clinical management of cancer patients based on a prospective data registry. The study was developed to inform consultations with public health insurances on PET/CT coverage. METHODS: We evaluated a prospective patient cohort having a clinically indicated PET/CT at a single German University Center from April 2013 to August 2016. The registry collected questionnaire data from requesting physicians on intended patient management before and after PET/CT. A total of 4,504 patients with 5,939 PET/CT examinations were enrolled in the registry, resulting in evaluable data from 3,724 patients receiving 4,754 scans. The impact of PET/CT on patient management was assessed across 22 tumor types, for different indications (diagnosis, staging, suspected recurrence) and different categories of management including treatment (curative or palliative) and non-treatment (watchful waiting, additional imaging, invasive tests). RESULTS: The most frequent PET/CT indication was tumor staging (59.7%). Melanoma, lung cancer, lymphoma, neuroendocrine tumor and prostate cancer accounted for 70% of cases. Overall, the use of PET/CT resulted in a 37.1% change of clinical management (95% CI, 35.7-38.5), most frequently (30.6%) from an intended non-treatment strategy before PET/CT to active treatment after PET/CT. The frequency of changes ranged from 28.3% for head and neck cancers up to 46.0% for melanomas. The impact of PET/CT was greatest in reducing demands for additional imaging which decreased from 66.1% before PET/CT to 6.1% after PET/CT. Pre-PET/CT planned invasive tests could be avoided in 72.7% of cases. The treatment goal changed after PET/CT in 21.7% of cases, in twice as many cases from curative to palliative therapy than vice versa. CONCLUSIONS: The data of this large prospective registry confirm that physicians often change their intended management on the basis of PET/CT by initiating treatment and reducing additional imaging as well as invasive tests. This applies to various cancer types and indications.
引用
- Pfannenberg C, Gueckel B, Wang L, et al. Practice-based evidence for the clinical benefit of PET/CT-results of the first oncologic PET/CT registry in Germany. Eur J Nucl Med Mol Imaging. 2018. PMID: 30269155. doi:10.1007/s00259-018-4156-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。